APVO (Aptevo Therapeutics) Float Percentage Of Total Shares Outstanding : 99.88% (As of Mar. 02, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aptevo Therapeutics's float shares is 1.46 Mil. Aptevo Therapeutics's total shares outstanding is 1.46 Mil. Aptevo Therapeutics's float percentage of total shares outstanding is 99.88%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aptevo Therapeutics's Insider Ownership is 5.31%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aptevo Therapeutics's Institutional Ownership is 3.33%.

Aptevo Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aptevo Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.46	/	1.46
	=	99.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptevo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121

Website

https://www.aptevotherapeutics.com

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Executives

Daphne Taylor	officer: SVP, CFO	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon	officer: See Remarks	APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux	officer: Senior VP, Operations	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White	director, officer: President and CEO	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi	director	2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell	officer: SVP, GC and Corporate Affairs	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman	officer: SVP, Commercial Operations	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross	officer: See Remarks	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121